BRPI0408116A - glicoproteìna hialuronidase solúvel (shasegp), processo para a sua preparação, usos e composições farmacêuticas compreendendo-a - Google Patents

glicoproteìna hialuronidase solúvel (shasegp), processo para a sua preparação, usos e composições farmacêuticas compreendendo-a

Info

Publication number
BRPI0408116A
BRPI0408116A BRPI0408116-1A BRPI0408116A BRPI0408116A BR PI0408116 A BRPI0408116 A BR PI0408116A BR PI0408116 A BRPI0408116 A BR PI0408116A BR PI0408116 A BRPI0408116 A BR PI0408116A
Authority
BR
Brazil
Prior art keywords
shasegp
hyaluronidase
pharmaceutical compositions
preparation
glycoprotein
Prior art date
Application number
BRPI0408116-1A
Other languages
English (en)
Inventor
Anirban Kundu
Louis H Bookbinder
Gregory I Frost
Original Assignee
Deliatroph Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32962713&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0408116(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Deliatroph Pharmaceuticals Inc filed Critical Deliatroph Pharmaceuticals Inc
Publication of BRPI0408116A publication Critical patent/BRPI0408116A/pt
Publication of BRPI0408116B1 publication Critical patent/BRPI0408116B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2474—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)

Abstract

"GLICOPROTEìNA HIALURONIDASE SOLúVEL (sHASEGP), PROCESSO PARA A SUA PREPARAçãO, USOS E COMPOSIçõES FARMACêUTICAS COMPREENDENDO-A". A invenção diz respeito à descoberta de novas Glicoproteínas Hialuronidase ativas neutras solúveis (sHASEGPs), métodos de fabricação, e seu uso para facilitar a administração de outras moléculas ou para aliviar as patologias associadas com glicosaminoglicano. Os domínios de polipeptídeo minimamente ativos dos domínios de SHASEGP ativos neutros solúveis são descritos os quais incluem peptídeos líderes que intensificam a secreção de sHASEGP. A invenção ainda compreende formas sialadas e pegiladas de uma sHASEGP recombinante para intensificar a estabilidade e os farmacocinéticos sobre as enzimas matadouras de ocorrência natural. Ainda descritas são as formulações adequadas de uma glicoproteína sHASEGP recombinante substancialmente purificada derivada de uma célula eucariótica que gera a própria glicosilação requerida com relação a sua atividade ideal.
BRPI0408116-1A 2003-03-05 2004-03-05 Polipeptídeos de hialuronidase solúveis conjugados a polímero, composições farmacêuticas compreendendo polipeptídeos ph20 solúveis, seus usos e processo de preparação, e ácidos nucléicos que codificam polipeptídeos de hialuronidase solúveis BRPI0408116B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45236003P 2003-03-05 2003-03-05
US60/452,360 2003-03-05
PCT/US2004/006656 WO2004078140A2 (en) 2003-03-05 2004-03-05 SOLUBLE HYALURONIDASE GLYCOPROTEIN (sHASEGP), PROCESS FOR PREPARING THE SAME, USES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEREOF

Publications (2)

Publication Number Publication Date
BRPI0408116A true BRPI0408116A (pt) 2006-03-01
BRPI0408116B1 BRPI0408116B1 (pt) 2022-09-20

Family

ID=32962713

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0408116-1A BRPI0408116B1 (pt) 2003-03-05 2004-03-05 Polipeptídeos de hialuronidase solúveis conjugados a polímero, composições farmacêuticas compreendendo polipeptídeos ph20 solúveis, seus usos e processo de preparação, e ácidos nucléicos que codificam polipeptídeos de hialuronidase solúveis

Country Status (26)

Country Link
US (14) US7767429B2 (pt)
EP (7) EP2177620B1 (pt)
JP (3) JP4464395B2 (pt)
KR (4) KR20050118273A (pt)
CN (2) CN102943067B (pt)
AT (1) ATE448323T1 (pt)
AU (2) AU2004218354B2 (pt)
BR (1) BRPI0408116B1 (pt)
CA (1) CA2517145C (pt)
CY (6) CY1109750T1 (pt)
DE (1) DE602004024041D1 (pt)
DK (4) DK2177620T3 (pt)
EA (1) EA009383B1 (pt)
ES (4) ES2526536T3 (pt)
FR (1) FR16C0030I1 (pt)
HU (2) HUE027661T2 (pt)
IL (2) IL170300A (pt)
LU (2) LU92780I2 (pt)
MX (1) MXPA05009429A (pt)
NZ (1) NZ542873A (pt)
PL (4) PL1603541T5 (pt)
PT (3) PT2163643E (pt)
SG (2) SG2012041067A (pt)
SI (4) SI2177620T1 (pt)
WO (1) WO2004078140A2 (pt)
ZA (1) ZA200507978B (pt)

Families Citing this family (297)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030212021A1 (en) * 2001-01-25 2003-11-13 Frost Gregory I. Myeloid colony stimulating factor and uses thereof
EP2218779A1 (en) 2002-12-16 2010-08-18 Halozyme, Inc. Human chondroitinase glycoprotein (chasegp), process for preparing the same, and pharmaceutical compositions comprising thereof
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US7767429B2 (en) 2003-03-05 2010-08-03 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US20090123367A1 (en) * 2003-03-05 2009-05-14 Delfmems Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases
US20060104968A1 (en) * 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US7572613B2 (en) * 2004-06-25 2009-08-11 Klein Jeffrey A Drug delivery system for accelerated subcutaneous absorption
EP2664334B1 (en) * 2004-12-30 2015-03-04 Genzyme Corporation Regimens for intra-articular viscosupplementation
CN103146708A (zh) 2005-06-30 2013-06-12 Abbvie公司 Il-12/p40结合蛋白
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
JP5364870B2 (ja) 2005-08-19 2013-12-11 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
EP2500353A3 (en) 2005-08-19 2012-10-10 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CN101277974A (zh) 2005-09-30 2008-10-01 阿伯特有限及两合公司 排斥性引导分子(rgm)蛋白质家族的蛋白质的结合结构域及其功能性片段和它们的用途
US8168206B1 (en) * 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
PT1976877E (pt) 2005-11-30 2014-04-29 Abbvie Inc Anticorpos monoclonais contra proteína beta-amilóide e suas utilizações
BRPI0619249A2 (pt) 2005-11-30 2011-09-20 Abbott Lab anticorpos anti-globulÈmeros-aß, frações que se ligam a antìgeno destes, hibridomas correspondentes, ácidos nucléicos, vetores, células hospedeiras, métodos de produzir os ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos de usar os ditos anticorpos
EP2004172B1 (en) 2006-03-31 2019-03-13 Mati Therapeutics Inc. Drug delivery structures and compositions for nasolacrimal system
PL3339445T3 (pl) 2006-09-08 2020-12-14 Abbvie Bahamas Ltd. Białka wiążące interleukinę 13
NZ576032A (en) 2006-10-12 2012-03-30 Genentech Inc Antibodies to lymphotoxin-alpha
US20080160003A1 (en) * 2006-10-31 2008-07-03 University Of Delaware Fertility Enhancement Using Lipid Carriers and Bioactive Molecules
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2124952A2 (en) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
US8288142B2 (en) * 2007-06-19 2012-10-16 Uvarkina Tamara P Hyaluronidase and method of use thereof
US9011361B2 (en) * 2007-09-07 2015-04-21 Mati Therapeutics Inc. Lacrimal implant detection
EP2214639A2 (en) * 2007-11-06 2010-08-11 Stuart L. Weg Anesthetic composition, formulation and method of use
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
TWI395593B (zh) 2008-03-06 2013-05-11 Halozyme Inc 可活化的基質降解酵素之活體內暫時性控制
CA2717383C (en) * 2008-03-06 2017-01-03 Halozyme, Inc. Large-scale production of soluble hyaluronidase
TWI532498B (zh) 2008-03-17 2016-05-11 巴克斯特保健公司 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
EP2662090A1 (en) * 2008-04-14 2013-11-13 Halozyme, Inc. Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
WO2009128918A1 (en) * 2008-04-14 2009-10-22 Halozyme, Inc. Combination therapy using a soluble hyaluronidase and a bisphosphonate
TWI394580B (zh) * 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
JP5646457B2 (ja) 2008-04-29 2014-12-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
RU2518351C2 (ru) 2008-05-09 2014-06-10 Эббви Дойчланд Гмбх Унд Ко.Кг, Антитела к рецептору конечных продуктов глубокого гликирования (rage) и их применения
EP3002299A1 (en) 2008-06-03 2016-04-06 AbbVie Inc. Dual variable domain immunoglobulins and uses thereof
PE20100054A1 (es) 2008-06-03 2010-03-03 Abbott Lab Inmunoglobulina con dominio variable dual
RU2559525C2 (ru) 2008-07-08 2015-08-10 Эббви Инк Белки, связывающие простагландин е2, и их применение
MX2010014574A (es) 2008-07-08 2011-04-27 Abbott Lab Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
TW201016233A (en) * 2008-07-15 2010-05-01 Genentech Inc Methods of treating autoimmune diseases using CD4 antibodies
EP2177227B1 (en) * 2008-10-14 2013-03-20 Burgard, Gunter, Dr. med. Use of hyaluronidase for the prevention or treatment of arterial hypertension.
GB0819883D0 (en) 2008-10-29 2008-12-03 Azyme Res As Product and uses
AU2013202000B2 (en) * 2008-12-09 2015-07-30 Halozyme, Inc. Extended soluble PH20 polypeptides and uses thereof
EA036569B1 (ru) * 2008-12-09 2020-11-24 Галозим, Инк. Способ получения полипептида гиалуронидазы ph20
US20100209558A1 (en) * 2009-02-19 2010-08-19 General Nutrition Corporation Dietary ingredient with enhanced bioavailability
TW201613969A (en) 2009-03-05 2016-04-16 Abbvie Inc IL-17 binding proteins
US20110229451A2 (en) * 2009-03-06 2011-09-22 Halozyme, Inc. Temperature sensitive mutants of matrix metalloproteases and uses thereof
US8283162B2 (en) 2009-03-10 2012-10-09 Abbott Laboratories Antibodies relating to PIVKAII and uses thereof
ES2385251B1 (es) 2009-05-06 2013-05-06 Fundació Privada Institut D'investigació Biomèdica De Bellvitge Adenovirus oncolíticos para el tratamiento del cáncer.
DE102009003291A1 (de) * 2009-05-20 2010-12-30 Henkel Ag & Co. Kgaa Kosmetische Zusammensetzung und Verformungsverfahren für keratinische Fasern
US20100305500A1 (en) * 2009-05-29 2010-12-02 Pacira Pharmaceuticals, Inc. Hyaluronidase as an adjuvant for increasing the injection volume and dispersion of large diameter synthetic membrane vesicles containing a therapeutic agent
WO2010146059A2 (en) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarkers for igf-1r inhibitor therapy
SG177424A1 (en) * 2009-06-29 2012-02-28 Univ Singapore Synthesis and use of fluorophore-tagged antimalarials
US8513259B2 (en) 2009-07-03 2013-08-20 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
US8263581B2 (en) 2009-07-03 2012-09-11 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
US9345661B2 (en) * 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
AR078254A1 (es) 2009-09-01 2011-10-26 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
CN102655853B (zh) 2009-09-17 2015-07-29 巴克斯特卫生保健有限公司 透明质酸酶和免疫球蛋白的稳定的复合制剂及其使用方法
MX2012004415A (es) 2009-10-15 2012-05-08 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2011053707A1 (en) 2009-10-31 2011-05-05 Abbott Laboratories Antibodies to receptor for advanced glycation end products (rage) and uses thereof
KR20120118002A (ko) 2009-12-08 2012-10-25 애보트 게엠베하 운트 콤파니 카게 망막 신경 섬유 층 변성의 치료에 사용하기 위한 ｒｇｍ ａ 단백질에 대한 모노클로날 항체
EP2558494B1 (en) 2010-04-15 2018-05-23 AbbVie Inc. Amyloid-beta binding proteins
AU2011252883B2 (en) 2010-05-14 2015-09-10 Abbvie Inc. IL-1 binding proteins
WO2012006500A2 (en) 2010-07-08 2012-01-12 Abbott Laboratories Monoclonal antibodies against hepatitis c virus core protein
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
MX348420B (es) 2010-07-20 2017-06-12 Halozyme Inc Efectos secundarios adversos asociados con la administracion de agentes anti-hialuronano y metodos para mejorar o prevenir los efectos secundarios.
US9120862B2 (en) 2010-07-26 2015-09-01 Abbott Laboratories Antibodies relating to PIVKA-II and uses thereof
US8735546B2 (en) 2010-08-03 2014-05-27 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
CN105348387B (zh) 2010-08-14 2020-08-25 Abbvie 公司 β淀粉样蛋白结合蛋白
PH12013500337A1 (en) 2010-08-26 2017-08-23 Abbvie Inc Dual variable domain immunoglobulins and uses thereof
MX349622B (es) 2010-09-08 2017-08-07 Halozyme Inc Metodos para evaluar e identificar o evolucionar proteinas terapeuticas condicionalmente activas.
US9414930B2 (en) 2010-10-26 2016-08-16 Kyphon SÀRL Activatable devices containing a chemonucleolysis agent
US8404268B2 (en) 2010-10-26 2013-03-26 Kyphon Sarl Locally targeted anti-fibrotic agents and methods of use
US8740982B2 (en) 2010-10-26 2014-06-03 Kyphon Sarl Devices containing a chemonucleolysis agent and methods for treating an intervertebral disc or spinal arachnoiditis
CN103260702B (zh) 2010-10-28 2018-07-27 帕西拉制药有限公司 非甾体类抗炎药的缓释制剂
EP2787007A3 (en) 2010-11-08 2015-03-11 F. Hoffmann-La Roche AG Subcutaneously administered ANTI-IL-6 receptor antibody
WO2012121775A2 (en) 2010-12-21 2012-09-13 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
US8703137B2 (en) 2011-01-31 2014-04-22 Intellect Neurosciences Inc. Treatment of tauopathies
ES2634669T3 (es) 2011-02-08 2017-09-28 Halozyme, Inc. Composición y formulación lipídica de una enzima de degradación de hialuronano y uso de la misma para el tratamiento de la hiperplasia benigna de próstata
US9993529B2 (en) 2011-06-17 2018-06-12 Halozyme, Inc. Stable formulations of a hyaluronan-degrading enzyme
MX341448B (es) 2011-06-17 2016-08-19 Halozyme Inc Metodos de infusion de insulina subcutanea continua con una enzima que degrada a hialuronano.
WO2012174478A2 (en) 2011-06-17 2012-12-20 Halozyme, Inc. Stable formulations of a hyaluronan-degrading enzyme
RU2640025C2 (ru) 2011-07-13 2017-12-25 Эббви Инк. Способы и композиции для лечения астмы с использованием антител против il-13
WO2013040501A1 (en) 2011-09-16 2013-03-21 Pharmathene, Inc. Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and uses thereof
AU2012328880B2 (en) 2011-10-24 2017-02-23 Halozyme, Inc. Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof
BR112014009810A2 (pt) 2011-10-24 2017-04-25 Abbvie Inc imunoligantes biespecíficos dirigidos contra tnf e il-17
EP2771360A1 (en) 2011-10-24 2014-09-03 AbbVie Inc. Immunobinders directed against sclerostin
CN104144947B (zh) 2011-12-14 2017-10-27 艾伯维德国有限责任两合公司 用于诊断和治疗铁相关病症的组合物和方法
EP2791175A2 (en) 2011-12-14 2014-10-22 Abbvie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of iron-related disorders
WO2013102144A2 (en) * 2011-12-30 2013-07-04 Halozyme, Inc. Ph20 polypeptede variants, formulations and uses thereof
US9120870B2 (en) 2011-12-30 2015-09-01 Abbvie Inc. Dual specific binding proteins directed against IL-13 and IL-17
EP3369746A1 (en) 2012-01-27 2018-09-05 AbbVie Deutschland GmbH & Co KG Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
NZ700073A (en) 2012-04-04 2016-08-26 Halozyme Inc Combination therapy with an anti - hyaluronan agent and a tumor - targeted taxane
EP2843051B1 (en) 2012-04-23 2018-06-06 GeneFrontier Corporation Anti-human cd69 antibody, and use thereof for medical purposes
TW201402608A (zh) 2012-07-12 2014-01-16 Abbvie Inc Ｉｌ－１結合蛋白質
EP2877589B1 (en) 2012-07-26 2024-03-06 Momenta Pharmaceuticals, Inc. Glycoproteins with anti-inflammatory properties
US9278124B2 (en) 2012-10-16 2016-03-08 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
AU2013337775B2 (en) 2012-11-01 2017-03-30 Abbvie Inc. Anti-VEGF/DLL4 dual variable domain immunoglobulins and uses thereof
KR101454646B1 (ko) * 2012-11-05 2014-10-27 (주)한국비엠아이 히알루로니다아제의 안정화 제제 및 이를 포함하는 액상제제
WO2014073292A1 (ja) 2012-11-09 2014-05-15 ジーンフロンティア株式会社 癌治療のための抗adam28抗体
US20150196625A9 (en) 2013-01-07 2015-07-16 Rudolph D. Paladini Metal Sensitive Mutants of Matrix Metalloproteases and uses thereof
CN105209033B (zh) 2013-03-14 2018-09-18 马萨诸塞大学 抑制白内障和老花眼的方法
US9469686B2 (en) 2013-03-15 2016-10-18 Abbott Laboratories Anti-GP73 monoclonal antibodies and methods of obtaining the same
EP2970459A2 (en) 2013-03-15 2016-01-20 AbbVie Inc. Dual specific binding proteins directed against il-1beta and il-17
TWI476203B (zh) 2013-03-18 2015-03-11 Ind Tech Res Inst 醣類的分離方法
WO2014165713A2 (en) 2013-04-03 2014-10-09 Cedars-Sinai Medical Center Treatment of inflammatory conditions by modulation of hyaluronan and hyaluronidase activity
US10464996B2 (en) 2013-05-13 2019-11-05 Momenta Pharmaceuticals, Inc. Methods for the treatment of neurodegeneration
WO2014197885A2 (en) 2013-06-07 2014-12-11 Duke University Inhibitors of complement factor h
WO2014200018A1 (ja) 2013-06-11 2014-12-18 独立行政法人 国立精神・神経医療研究センター 再発寛解型多発性硬化症（ｒｒｍｓ）患者の治療予後予測方法、及び新規治療適応判断方法
TW201534726A (zh) 2013-07-03 2015-09-16 Halozyme Inc 熱穩定ｐｈ２０玻尿酸酶變異體及其用途
AU2014284396A1 (en) 2013-07-03 2016-02-04 City Of Hope Anticancer combinations
CA2920835A1 (en) 2013-08-20 2015-02-26 Anutra Medical, Inc. Syringe fill system and method
US9968623B2 (en) * 2013-08-29 2018-05-15 Lanny Leo Johnson Prepackaged sterile syringe or containers with various substance concentrations with or without bioactive reagent
IL312865B2 (en) 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
RS65724B1 (sr) 2013-10-15 2024-08-30 Genefrontier Corp Humano antitelo protiv adamts vrste tipa agrekanaze za terapeutike bolesti povezanih sa agrekanazom
WO2015057622A1 (en) 2013-10-16 2015-04-23 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
WO2015084883A2 (en) 2013-12-02 2015-06-11 Abbvie, Inc. Compositions and methods for treating osteoarthritis
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
WO2015138337A1 (en) 2014-03-09 2015-09-17 Abbvie, Inc. Compositions and methods for treating rheumatoid arthritis
TW202214691A (zh) 2014-03-21 2022-04-16 美商艾伯維有限公司 抗-egfr抗體及抗體藥物結合物
US10117886B2 (en) 2014-05-30 2018-11-06 Hao Cheng Hyaluronidase and a low density second PEG layer on the surface of therapeutic-encapsulated nanoparticles to enhance nanoparticle diffusion and circulation
USD763433S1 (en) 2014-06-06 2016-08-09 Anutra Medical, Inc. Delivery system cassette
USD750768S1 (en) 2014-06-06 2016-03-01 Anutra Medical, Inc. Fluid administration syringe
USD774182S1 (en) 2014-06-06 2016-12-13 Anutra Medical, Inc. Anesthetic delivery device
US20160002326A1 (en) 2014-06-10 2016-01-07 Abbvie Inc. Compositions and methods for treating rheumatoid arthritis
CA2958145C (en) * 2014-07-16 2023-09-26 New York University Use of hyaluronidase for treatment of muscle stiffness
EP3186281B1 (en) 2014-08-28 2019-04-10 Halozyme, Inc. Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor
PE20170676A1 (es) 2014-09-09 2017-05-22 Janssen Biotech Inc Terapias de combinacion con anticuerpos anti-cd38
PL3193952T3 (pl) * 2014-09-18 2019-09-30 Chondronest Sa Kompozycja zawierająca glikozaminoglikany i białka
SG11201702614SA (en) 2014-10-01 2017-04-27 Eagle Biolog Inc Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
BR112017007765B1 (pt) 2014-10-14 2023-10-03 Halozyme, Inc Composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo
EA202092609A1 (ru) 2014-12-04 2021-10-29 Янссен Байотек, Инк. Антитела к cd38 для лечения острого миелолейкоза
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
WO2016137471A1 (en) * 2015-02-26 2016-09-01 Nantpharma, Llc Method for enhanced heparin quality
US9981021B1 (en) 2015-04-09 2018-05-29 Kinetiq, Inc. Subcutaneous therapeutic enzyme formulations, uses, and methods for generating thereof
CA2986594C (en) 2015-05-20 2025-06-10 Tufts Medical Center, Inc. Anti-CD38 antibodies for the treatment of light chain amyloidosis and other CD38-positive hematological malignancies
RU2715597C2 (ru) 2015-05-29 2020-03-02 Эббви Инк. Антитела к cd40 и способы их применения
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
CN107708734B (zh) * 2015-06-22 2022-01-11 詹森生物科技公司 用抗cd38抗体和生存素抑制剂联合治疗血红素恶性肿瘤
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
HRP20240338T1 (hr) 2015-06-24 2024-05-24 Janssen Biotech, Inc. Imunomodulacija i liječenje solidnih tumora s protutijelima koja se specifično vežu na cd38
BR112018004867A2 (pt) 2015-09-11 2018-10-16 Abbvie Deutschland métodos para tratamento das formas recorrentes de esclerose múltipla
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
HUE053366T2 (hu) * 2015-11-03 2021-06-28 Janssen Biotech Inc Szubkután anti-CD38-ellenanyag-készítmények és alkalmazásuk
CN108348494A (zh) 2015-11-13 2018-07-31 马萨诸塞大学 用于抑制白内障和老花眼的含peg的双官能分子
ITUB20159209A1 (it) 2015-12-21 2017-06-21 Fidia Farm Spa Nanosistemi per il trasporto controllato di molecole attive a fini diagnostici, prognostici e terapeutici
US10493247B2 (en) 2016-03-15 2019-12-03 Medtronic Holding Company Sàrl Devices for delivering a chemical denervation agent and methods of use
WO2017161206A1 (en) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
JP7082604B2 (ja) 2016-03-21 2022-06-08 マレンゴ・セラピューティクス，インコーポレーテッド 多重特異性および多機能性分子ならびにその使用
JP2019517480A (ja) 2016-06-01 2019-06-24 アッヴィ・インコーポレイテッド 脊髄損傷及び疼痛を処置するための抗ＲＧＭａ（Ｒｅｐｕｌｓｉｖｅ Ｇｕｉｄａｎｃｅ Ｍｏｌｅｃｕｌｅ Ａ）アンタゴニスト抗体
CA3027044A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
TWI762487B (zh) 2016-06-08 2022-05-01 美商艾伯維有限公司 抗-b7-h3抗體及抗體藥物結合物
EP3468598A1 (en) 2016-06-08 2019-04-17 AbbVie Inc. Anti-cd98 antibodies and antibody drug conjugates
US20190233533A1 (en) 2016-06-28 2019-08-01 Umc Utrecht Holding B.V. Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38
IL265109B2 (en) 2016-09-13 2024-05-01 Allergan Inc Stabilized non-protein clostridial toxin compositions
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
TWI826360B (zh) 2016-11-17 2023-12-21 美商艾歐凡斯生物治療公司 殘餘腫瘤浸潤性淋巴細胞及製備和使用彼之方法
WO2018091151A1 (en) * 2016-11-17 2018-05-24 Vcn Biosciences Sl Use of viral vectors in the treatment of retinoblastoma
CN109983013A (zh) 2016-11-18 2019-07-05 帕西拉制药有限公司 美洛昔康锌复合物微粒多囊脂质体制剂及其制备方法
EP3544628A4 (en) 2016-11-23 2020-11-18 Immunoah Therapeutics, Inc. 4-1BB BINDING PROTEINS AND THEIR USES
MY189536A (en) 2017-01-17 2022-02-16 Hoffmann La Roche Subcutaneous her2 antibody formulations
WO2018183928A1 (en) 2017-03-31 2018-10-04 Bristol-Myers Squibb Company Methods of treating tumor
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
US10865238B1 (en) 2017-05-05 2020-12-15 Duke University Complement factor H antibodies
RU2651756C1 (ru) * 2017-05-10 2018-04-23 Федеральное государственное бюджетное образовательное учреждение Высшего Образования Кубанский Государственный Медицинский Университет Министерства Здравоохранения Российской Федерации, КубГМУ Препарат для предотвращения образования глиальных рубцов
WO2019075468A1 (en) 2017-10-15 2019-04-18 Bristol-Myers Squibb Company TUMOR TREATMENT METHODS
CN111565751A (zh) 2017-10-31 2020-08-21 詹森生物科技公司 治疗高危多发性骨髓瘤的方法
WO2019090330A1 (en) 2017-11-06 2019-05-09 Bristol-Myers Squibb Company Methods of treating a tumor
US12042528B2 (en) 2017-12-29 2024-07-23 The Trustees Of Columbia University In The City Of New York Hyaluronidase for the prevention, treatment, reduction and/or abolishment of cerebral edema and intracranial pressure
WO2019139987A1 (en) 2018-01-09 2019-07-18 Elstar Therapeutics, Inc. Calreticulin binding constructs and engineered t cells for the treatment of diseases
US20230181635A1 (en) 2018-03-13 2023-06-15 Fundación Para La Investigación Biomédica Del Hospital Universitario La Paz Anti-cxcr4 antibody combined with activated and expanded natural killer cells for cancer immunotherapy
US12152073B2 (en) 2018-03-14 2024-11-26 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
EP3765516A2 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules and uses thereof
WO2019182745A1 (en) 2018-03-19 2019-09-26 Bryn Pharma, LLC Epinephrine spray formulations
CA3093407A1 (en) 2018-03-23 2019-09-26 Bristol-Myers Squibb Company Antibodies against mica and/or micb and uses thereof
KR20200139724A (ko) 2018-03-30 2020-12-14 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법
JP7680208B2 (ja) 2018-04-04 2025-05-20 ブリストル－マイヤーズ スクイブ カンパニー 抗ｃｄ２７抗体およびその使用
EP4066830A1 (en) 2018-04-24 2022-10-05 Allergan, Inc. Use of pilocarpine hydrochloride for the treatment of ocular conditions
SG11202011306TA (en) 2018-05-16 2020-12-30 Janssen Biotech Inc Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy
US20190351031A1 (en) 2018-05-16 2019-11-21 Halozyme, Inc. Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
WO2019232512A1 (en) * 2018-06-01 2019-12-05 Musc Foundatiion For Research Development Glycan analysis of proteins and cells
CN119930818A (zh) 2018-06-29 2025-05-06 爱必泰生物有限公司 抗l1cam抗体及其用途
WO2020010250A2 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
WO2020022791A1 (ko) 2018-07-25 2020-01-30 (주)알테오젠 신규 히알루론산 가수분해 효소 변이체 및 이를 포함하는 약제학적 조성물
WO2020076799A1 (en) 2018-10-09 2020-04-16 Bristol-Myers Squibb Company Anti-mertk antibodies for treating cancer
BR112021007227A2 (pt) 2018-10-17 2021-08-10 Janssen Biotech, Inc. método para fornecer administração subcutânea de anticorpos anti-cd38
KR20210081384A (ko) 2018-10-23 2021-07-01 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법
WO2020092546A1 (en) 2018-10-30 2020-05-07 Alexion Pharmaceuticals, Inc. Co-administration of a hyaluronidase and anti-c5 antibody for treatment of complement-associated conditions
AU2019379858B2 (en) 2018-11-13 2024-01-04 Janssen Biotech, Inc. Control of trace metals during production of anti-CD38 antibodies
CN109679823B (zh) * 2018-11-19 2022-03-15 江苏汇先医药技术有限公司 一种用于生物分子、细胞或细菌的捕获材料及捕获筛
AU2020226904B2 (en) 2019-02-21 2025-05-01 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
GB2597851B (en) 2019-02-21 2024-05-29 Marengo Therapeutics Inc Antibody molecules that bind to NKP30 and uses thereof
AU2020226893B2 (en) 2019-02-21 2025-02-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cell related cancer cells and uses thereof
CN112203642B (zh) * 2019-03-25 2025-03-07 阿特根公司 用于皮下注射的包含人透明质酸酶ph20变体和药物的药物组合物
US20220195046A1 (en) 2019-03-28 2022-06-23 Bristol-Myers Squibb Company Methods of treating tumor
WO2020198672A1 (en) 2019-03-28 2020-10-01 Bristol-Myers Squibb Company Methods of treating tumor
CA3135170A1 (en) 2019-04-05 2020-10-08 Tauc3 Biologics Limited Anti-tauc3 antibodies and uses thereof
ES3029282T3 (en) * 2019-05-07 2025-06-23 Genzyme Corp Methods for quantifying drug concentration in a prodrug composition
US20220193149A1 (en) * 2019-05-16 2022-06-23 City Of Hope Compositions and methods for targeting tumor-associated extracellular matrix components to improve drug delivery
WO2020241340A1 (ja) * 2019-05-24 2020-12-03 株式会社糖鎖工学研究所 新規な人工タンパク質触媒
CN114174538A (zh) 2019-05-30 2022-03-11 百时美施贵宝公司 适合于免疫肿瘤学疗法的多肿瘤基因特征
CN114174537A (zh) 2019-05-30 2022-03-11 百时美施贵宝公司 细胞定位特征和组合疗法
WO2020243568A1 (en) 2019-05-30 2020-12-03 Bristol-Myers Squibb Company Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy
MX2022002747A (es) 2019-09-10 2022-04-06 Obsidian Therapeutics Inc Proteinas de fusion de ca2-il15 para regulacion ajustable.
JP7739269B2 (ja) 2019-09-25 2025-09-16 ブリストル－マイヤーズ スクイブ カンパニー がん療法のための複合バイオマーカー
US20240156920A1 (en) * 2019-10-15 2024-05-16 Standard Of Care Corporation Compositions comprising hyaluronidase and/or collagenase and/or 4-methylumbelliferone (4-mu) and methods of treatment using same
WO2021092220A1 (en) 2019-11-06 2021-05-14 Bristol-Myers Squibb Company Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
WO2021092221A1 (en) 2019-11-06 2021-05-14 Bristol-Myers Squibb Company Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
EP4054723A1 (en) 2019-11-08 2022-09-14 Bristol-Myers Squibb Company Lag-3 antagonist therapy for melanoma
CR20220322A (es) 2019-12-09 2022-07-28 Genentech Inc Formulaciones de anticuerpos anti-pd-l1
WO2021138407A2 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Multifunctional molecules that bind to cd33 and uses thereof
AU2020416273A1 (en) 2020-01-03 2022-07-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
CN121472194A (zh) 2020-01-23 2026-02-06 阿特根公司 具有改善的稳定性的新玻尿酸酶变体及含有其的药物组合物
EP4106798A1 (en) 2020-02-17 2022-12-28 Biotest AG Subcutaneous administration of factor viii
CN115768792A (zh) 2020-03-23 2023-03-07 百时美施贵宝公司 抗ccr8抗体用于治疗癌症
CN111529685A (zh) * 2020-04-21 2020-08-14 厦门诺康得生物科技有限公司 抗呼吸道病毒感染的鼻腔喷雾制剂
KR20230012539A (ko) 2020-05-13 2023-01-26 디스크 메디슨, 인크. 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
CN116194478A (zh) 2020-06-24 2023-05-30 阿雷克森制药公司 皮下（sc）施用抗c5抗体治疗补体相关病症
EP4171748A1 (en) 2020-06-29 2023-05-03 Genentech, Inc. Pertuzumab plus trastuzumab fixed dose combination
MX2023000622A (es) 2020-07-14 2023-02-22 Genentech Inc Ensayos para combinaciones de dosis fija.
CN115776909A (zh) * 2020-07-17 2023-03-10 美国杰龙生物医药公司 皮下端粒酶抑制剂组合物及其使用方法
JP7622088B2 (ja) 2020-08-07 2025-01-27 アルテオジェン・インコーポレイテッド 組換えヒアルロニダーゼの生産方法
CN111759732B (zh) * 2020-08-12 2024-12-06 河南省人民医院 一种用于外周血造血干细胞冻存的多通道连接管路及方法
GB2616354A (en) 2020-08-26 2023-09-06 Marengo Therapeutics Inc Methods of detecting TRBC1 or TRBC2
CN116249718A (zh) 2020-08-26 2023-06-09 马伦戈治疗公司 结合至钙网蛋白的多功能性分子及其用途
CA3193421A1 (en) 2020-08-28 2022-03-03 Bristol-Myers Squibb Company Lag-3 antagonist therapy for hepatocellular carcinoma
CA3190660A1 (en) 2020-08-31 2022-03-03 George C. Lee Cell localization signature and immunotherapy
US20240101666A1 (en) 2020-10-23 2024-03-28 Bristol-Myers Squibb Company Lag-3 antagonist therapy for lung cancer
CN112168838A (zh) * 2020-10-23 2021-01-05 中国科学院动物研究所 透明质酸及其盐的治疗用途
US20220133861A1 (en) * 2020-10-30 2022-05-05 Standard Of Care Corporation Hyaluronidase compositions and methods of using same to treat edema
AU2021382120A1 (en) 2020-11-17 2023-07-06 Janssen Sciences Ireland Unlimited Company Treatment or prevention of a disease or disorder
WO2022109555A1 (en) 2020-11-17 2022-05-27 Janssen Sciences Ireland Unlimited Company Treatment or prevention of hiv infection
CN116437923A (zh) * 2020-11-17 2023-07-14 爱尔兰詹森科学公司 Hiv感染的治疗或预防
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
JP2024501029A (ja) 2020-12-28 2024-01-10 ブリストル－マイヤーズ スクイブ カンパニー Ｐｄ１／ｐｄ－ｌ１抗体の皮下投与
SMT202500208T1 (it) 2020-12-28 2025-07-22 Bristol Myers Squibb Co Composizioni anticorpali e metodi per il loro uso
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
US20220275090A1 (en) 2021-02-22 2022-09-01 Janssen Biotech, Inc. Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors
CN114350639B (zh) * 2021-03-05 2023-06-02 华熙生物科技股份有限公司 一种密码子优化的透明质酸水解酶基因及其表达
CN113025599B (zh) * 2021-04-02 2023-09-12 重庆科润生物医药研发有限公司 一种重组溶组织梭菌i型胶原酶及其制备方法和应用
EP4314068A1 (en) 2021-04-02 2024-02-07 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
JP2024515591A (ja) 2021-04-08 2024-04-10 マレンゴ・セラピューティクス，インコーポレーテッド Ｔｃｒに結合する多機能性分子およびその使用
TW202305009A (zh) 2021-04-08 2023-02-01 美商默沙東有限責任公司 以皮下投予抗pd1抗體治療癌症之方法
US20220332822A1 (en) 2021-04-16 2022-10-20 Tiziana Life Sciences Plc Subcutaneous administration of antibodies for the treatment of disease
TW202308689A (zh) 2021-04-21 2023-03-01 美商健生生物科技公司 高濃度的雙特異性抗體調配物
WO2022251645A1 (en) 2021-05-27 2022-12-01 Steiner Ventures Llc Hyaluronidase composition for intravenous administration and method of using the same
CN115671267A (zh) 2021-07-23 2023-02-03 上海宝济药业有限公司 一种皮下抗生素药物组合物
CN117693362A (zh) * 2021-08-02 2024-03-12 甘李药业股份有限公司 含有抗il-4r抗体的稳定制剂
TW202320849A (zh) 2021-08-02 2023-06-01 比利時商阿根思公司 皮下用單位劑型
CA3232451A1 (en) 2021-09-14 2023-03-23 Takeda Pharmaceutical Company Limited Facilitated delivery of concentrated antibody formulations using hyaluronidase
US20240417473A1 (en) 2021-10-29 2024-12-19 Bristol-Myers Squibb Company Lag-3 antagonist therapy for hematological cancer
US20250009850A1 (en) * 2021-10-29 2025-01-09 Alteogen, Inc. Pharmaceutical composition comprising human hyaluronidase ph20 and drug
WO2023081705A1 (en) 2021-11-03 2023-05-11 Janssen Biotech, Inc. Methods of treating cancers and enhancing efficacy of bcmaxcd3 bispecific antibodies
US20230134748A1 (en) 2021-11-03 2023-05-04 Janssen Biotech, Inc. Corticosteriod Reduction in Treatment with Anti-CD38 Antibody
EP4442733B1 (en) * 2022-01-14 2025-09-10 Jenkem Technology Co., Ltd. (Tianjin) Hyaluronic acid derivative or salt thereof, and preparation method therefor and application thereof
IL314050A (en) 2022-01-26 2024-09-01 Bristol Myers Squibb Co Combination therapy for hepatocellular carcinoma
US20250179174A1 (en) 2022-02-25 2025-06-05 Bristol-Myers Squibb Company Combination therapy for colorectal carcinoma
US20250099612A1 (en) 2022-03-01 2025-03-27 Exuma Biotech Corp. Viral particles with membrane-bound hyaluronidase
WO2023168404A1 (en) 2022-03-04 2023-09-07 Bristol-Myers Squibb Company Methods of treating a tumor
CN114634920B (zh) * 2022-03-24 2024-02-27 江南大学 一种产人源透明质酸酶ph20的重组毕赤酵母及其构建方法
US20260042840A1 (en) 2022-04-07 2026-02-12 Bristol-Myers Squibb Company Methods of treating tumor
CA3249515A1 (en) 2022-04-22 2023-10-26 Janssen Sciences Ireland Unlimited Company LIQUID COMPOSITIONS
CN119403545A (zh) 2022-04-22 2025-02-07 爱尔兰詹森科学公司 冷冻干燥的组合物
US20260028409A1 (en) 2022-05-24 2026-01-29 Bristol-Myers Squibb Company Antibodies that bind to human ccr8
CN119562830A (zh) 2022-06-02 2025-03-04 百时美施贵宝公司 抗体组合物及其使用方法
IL320562A (en) 2022-11-02 2025-07-01 Janssen Biotech Inc Cancer treatment methods
CN120731228A (zh) 2022-12-21 2025-09-30 百时美施贵宝公司 肺癌的组合疗法
CR20250293A (es) 2022-12-22 2025-09-18 Halozyme Inc Formulaciones de enzima hialuronidasa para la administración de alto volumen
KR20250152101A (ko) 2023-03-13 2025-10-22 하이델베르크 파마 리서치 게엠베하 암 치료에의 사용을 위한 피하 투여 항체-약물 접합체
CN116253809B (zh) * 2023-04-19 2024-11-05 广州润虹医药科技股份有限公司 一种去除壳聚糖中内毒素的方法
WO2025059266A1 (en) * 2023-09-12 2025-03-20 Sentrimed, Inc. Soluble recombinant human podoplanin receptor
CN121985959A (zh) 2023-09-26 2026-05-05 武田药品工业株式会社 耗减IgA的免疫球蛋白制剂
AU2024360739A1 (en) 2023-10-12 2026-04-02 Janssen Biotech, Inc. Methods for treating multiple myeloma comprising an anti-cd38 antibody combined with bortezomib, lenalidomide and dexamethasone
WO2025096611A1 (en) * 2023-11-02 2025-05-08 Siemens Healthcare Diagnostics Inc. Reagent compositions for immunoassays and use of the same in detection of cancer antigen 19-9
CN117887691B (zh) * 2023-12-27 2024-07-12 山东福瑞达医药集团有限公司 一种透明质酸酶融合蛋白、酵母工程菌及构建方法与应用
WO2025155877A2 (en) 2024-01-18 2025-07-24 The Regents Of The University Of California Antibodies binding to pad4 and uses thereof
EP4716552A1 (en) 2024-01-22 2026-04-01 Janssen Biotech, Inc. Use of amivantamab to treat head and neck cancer
WO2025191459A1 (en) 2024-03-11 2025-09-18 Janssen Biotech, Inc. Use of bispecific anti-egfr/c-met antibodies to treat solid tumors
KR102687341B1 (ko) * 2024-04-09 2024-07-23 주식회사 휴온스랩 온전한 형태의 히알루로니다제의 생산방법
WO2025245489A1 (en) 2024-05-24 2025-11-27 Bristol-Myers Squibb Company Treatment of tumors in subjects having fgl-1 positive samples
WO2025248465A1 (en) 2024-05-29 2025-12-04 Janssen Biotech, Inc. Treatment of locally advanced or metastatic egfr-mutated non-small cell lung cancer
WO2025262427A1 (en) 2024-06-19 2025-12-26 Levicept Limited Injectable formulation
WO2025264960A1 (en) 2024-06-21 2025-12-26 Apogee Therapeutics, Inc. Antibodies that bind il-13 and antibodies that bind ox40l
WO2025264972A1 (en) 2024-06-21 2025-12-26 Apogee Therapeutics, Inc. Antibodies that bind il-4r alpha and antibodies that bind
WO2026022733A1 (en) 2024-07-23 2026-01-29 Janssen Biotech, Inc. Combination therapies for the treatment of colorectal cancer
WO2026022739A1 (en) 2024-07-23 2026-01-29 Janssen Biotech, Inc. Combination therapies for the treatment of colorectal cancer
IL327429A (en) 2024-08-01 2026-05-01 Janssen Biotech Inc Daratumumab, bortezomib, lenalidomide, and dexamethasone for the treatment of multiple myeloma
WO2026028163A1 (en) 2024-08-01 2026-02-05 Janssen Biotech, Inc. Methods for treating high-risk smoldering multiple myeloma
US20260102490A1 (en) 2024-10-11 2026-04-16 Janssen Biotech, Inc. Combination of trispecific antibody targeting bcma, gprc5d and cd3, and an anti-cd38 antibody for the treatment of multiple myeloma
CN118969102B (zh) * 2024-10-18 2025-02-18 南京汉卫公共卫生研究院有限公司 一种基于数据融合分析的肿瘤组织分子智能分析识别系统
WO2026085417A2 (en) 2024-10-18 2026-04-23 Apogee Therapeutics, Inc. Antibodies that bind interleukin 4 receptor alpha in combination with hyaluronidase or a variant thereof
WO2026085414A1 (en) 2024-10-18 2026-04-23 Apogee Therapeutics, Inc. Antibodies that bind tslp and antibodies that bind interleukin 4 receptor alpha in combination with hyaluronidase or a variant thereof
WO2026085415A1 (en) 2024-10-18 2026-04-23 Apogee Therapeutics, Inc. Antibodies that bind il-13 and antibodies that bind tslp in combination with hyaluronidase or a variant thereof
WO2026085419A2 (en) 2024-10-18 2026-04-23 Apogee Therapeutics, Inc. Antibodies that bind il-13 in combination with hyaluronidase or a variant thereof

Family Cites Families (178)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US53247A (en) * 1866-03-13 Improved process for disintegrating fibers
US345770A (en) * 1886-07-20 Halp to nathan s
US305500A (en) * 1884-09-23 Window-bead fastener
US172892A (en) * 1876-02-01 Improvement in restaurant check-boxes
US8309A (en) * 1851-08-26 Washing-machine
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3630200A (en) 1969-06-09 1971-12-28 Alza Corp Ocular insert
US3639200A (en) * 1969-12-19 1972-02-01 Armin Elmendorf Textured wood panel
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US3847770A (en) 1972-04-10 1974-11-12 Continental Can Co Photopolymerizable compositions prepared from beta hydroxy esters and polyitaconates
GB1429184A (en) 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
US4044126A (en) 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
USRE28819E (en) 1972-12-08 1976-05-18 Syntex (U.S.A.) Inc. Dialkylated glycol compositions and medicament preparations containing same
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
JPS6033474B2 (ja) * 1978-05-11 1985-08-02 藤沢薬品工業株式会社 新規なヒアルロニダ−ゼｂｍｐ−８２３１およびその製造法
US4573994A (en) 1979-04-27 1986-03-04 The Johns Hopkins University Refillable medication infusion apparatus
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4358603A (en) 1981-04-16 1982-11-09 Syntex (U.S.A.) Inc. Acetal stabilized prostaglandin compositions
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4952496A (en) 1984-03-30 1990-08-28 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
EP0162007A1 (de) * 1984-04-18 1985-11-21 Geriaco AG Stabiles, lagerungsfähiges Insulinpräparat zur Behandlung von Akne vulgaris
US4769027A (en) 1984-08-15 1988-09-06 Burroughs Wellcome Co. Delivery system
GB8504025D0 (en) 1985-02-16 1985-03-20 Biopharm Ltd Hyaluronidase
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US4687610A (en) 1986-04-30 1987-08-18 E. I. Du Pont De Neumours And Company Low crystallinity polyester yarn produced at ultra high spinning speeds
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
WO1988002261A1 (fr) 1986-09-30 1988-04-07 Biochemie Gesellschaft M.B.H. Utilisation de hyaluronidase
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US5723147A (en) 1987-02-23 1998-03-03 Depotech Corporation Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5041292A (en) 1988-08-31 1991-08-20 Theratech, Inc. Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents
US5033352A (en) 1989-01-19 1991-07-23 Yamaha Corporation Electronic musical instrument with frequency modulation
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
EP0400472B1 (en) 1989-05-27 1996-04-03 Sumitomo Pharmaceuticals Company, Limited Process for preparing polyethylene glycol derivatives and modified protein.
DE3921528A1 (de) 1989-06-30 1991-01-10 Draegerwerk Ag Messzelle fuer den elektrochemischen gasnachweis
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5215899A (en) 1989-11-09 1993-06-01 Miles Inc. Nucleic acid amplification employing ligatable hairpin probe and transcription
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
ZA912770B (en) 1990-04-16 1992-01-29 Bethesda Eye Inst Enzymatic disinsertion of vitreous body
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5401629A (en) 1990-08-07 1995-03-28 The Salk Institute Biotechnology/Industrial Associates, Inc. Assay methods and compositions useful for measuring the transduction of an intracellular signal
CA2092323A1 (en) 1990-10-01 1992-04-02 George Y. Wu Targeting viruses and cells for selective internalization by cells
US5721348A (en) * 1990-12-14 1998-02-24 University Of Connecticut DNA encoding PH-20 proteins
DE69218811T2 (de) * 1991-01-23 1997-07-17 Matsushita Electric Industrial Co., Ltd., Kadoma, Osaka Wasser- und ölabweisender adsorbierter Film und Verfahren zu dessen Herstellung
AU668505B2 (en) 1991-03-18 1996-05-09 Scripps Research Institute, The Oligosaccharide enzyme substrates and inhibitors: methods and compositions
AU668870B2 (en) 1991-05-14 1996-05-23 Targetech, Inc Targeted delivery of genes encoding immunogenic proteins
WO1992022635A1 (en) 1991-06-05 1992-12-23 University Of Connecticut Targeted delivery of genes encoding secretory proteins
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
WO1993014188A1 (en) 1992-01-17 1993-07-22 The Regents Of The University Of Michigan Targeted virus
CA2133411A1 (en) 1992-04-03 1993-10-14 Alexander T. YOUNG Gene therapy using targeted viral vectors
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US5496718A (en) 1992-06-26 1996-03-05 Seikagaku Kogyo Kabushiki Kaisha (Seikagaku Corporation) Chondroitinase ABC isolated from proteus vulgaris ATCC 6896
JP3980657B2 (ja) 1992-06-26 2007-09-26 生化学工業株式会社 コンドロイチナーゼａｂｃ、その製造法及び医薬組成物
PT671923E (pt) 1992-10-09 2001-10-30 Advanced Tissue Sciences Inc Celulas de reserva do figado
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US5395619A (en) 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
US5354566A (en) 1993-06-02 1994-10-11 Kraft General Foods, Inc. Preparation of yeast-leavened dough crusts
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5766627A (en) 1993-11-16 1998-06-16 Depotech Multivescular liposomes with controlled release of encapsulated biologically active substances
ATE277640T1 (de) 1994-03-07 2004-10-15 Dow Chemical Co Bioaktive und/oder gezielte dendrimere-konjugate enthaltend genetisches material
US5795569A (en) 1994-03-31 1998-08-18 Amgen Inc. Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation
DE69503849T2 (de) 1994-03-31 1999-04-01 Amgen Inc., Thousand Oaks, Calif. Zusammensetzungen und Verfahren zur Anregung des Wachstums und der Differenzierung von Megakaryozyten
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5747027A (en) 1995-04-07 1998-05-05 The Regents Of The University Of California BH55 hyaluronidase
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
AU730969B2 (en) * 1995-10-19 2001-03-22 University Of Washington Discrete-length polyethylene glycols
US6610292B2 (en) 1995-11-22 2003-08-26 Ista Pharmaceuticals, Inc. Use of hyaluronidase in the manufacture of an ophthalmic preparation for liquefying vitreous humor in the treatment of eye disorders
US6828431B1 (en) * 1999-04-09 2004-12-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6784023B2 (en) * 1996-05-20 2004-08-31 Micron Technology, Inc. Method of fabrication of stacked semiconductor devices
ES2248847T3 (es) 1996-05-24 2006-03-16 Angiotech Pharmaceuticals, Inc. Composiciones y metodos para tratar o prevenir enfermedades de las vias de conduccion del cuerpo.
US5958750A (en) * 1996-07-03 1999-09-28 Inctye Pharmaceuticals, Inc. Human hyaluronidase
US5665069A (en) * 1996-07-19 1997-09-09 Cumer; Patricia Lynn Pressure-directed peribulbar anesthesia delivery device
US6214966B1 (en) 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
US6123938A (en) 1996-10-17 2000-09-26 The Regents Of The University Of California Human urinary hyaluronidase
US6103525A (en) 1996-10-17 2000-08-15 The Regents Of The University Of California Hybridoma cell lines producing monoclonal antibodies that bind to human plasma hyaluronidase
US6193963B1 (en) 1996-10-17 2001-02-27 The Regents Of The University Of California Method of treating tumor-bearing patients with human plasma hyaluronidase
US6331289B1 (en) 1996-10-28 2001-12-18 Nycomed Imaging As Targeted diagnostic/therapeutic agents having more than one different vectors
US6258351B1 (en) 1996-11-06 2001-07-10 Shearwater Corporation Delivery of poly(ethylene glycol)-modified molecules from degradable hydrogels
US5990237A (en) 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
DK0983084T3 (da) 1997-05-22 2007-05-07 Ista Pharmaceuticals Inc Anvendelse af hyaluronidase til fremstilling af et öjenpræparat til flydendegörelse af glaslegemet i behandlingen af öjenlidelser
FR2763958A1 (fr) * 1997-05-29 1998-12-04 Transgene Sa Produit de combinaison associant un acide nucleique a une substance desorganisant la matrice extracellulaire pour la therapie genique
SE512633C2 (sv) * 1997-07-09 2000-04-17 Cecilia Johnsson Användning av hyaluronidas för reduktion av inflammatoriska cellinfiltrat
US6448369B1 (en) 1997-11-06 2002-09-10 Shearwater Corporation Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
US5985263A (en) 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6362254B2 (en) 1998-03-12 2002-03-26 Shearwater Corporation Poly(ethylene glycol) derivatives with proximal reactive groups
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
KR20010041235A (ko) 1998-12-23 2001-05-15 이데 파르마 게엠베하 히알루론 산을 소화하는 미생물 효소를 함유하는 약학적제제
US6528797B1 (en) * 1999-04-16 2003-03-04 The Regents Of The University Of Michigan Method and system for determining depth distribution of radiation-emitting material located in a source medium and radiation detector system for use therein
JP2002543143A (ja) * 1999-04-29 2002-12-17 イスタ・ファーマスーティカルズ・インコーポレイテッド 角膜の瘢痕、混濁およびかすみを無くす生化学的方法
JO2291B1 (en) 1999-07-02 2005-09-12 اف . هوفمان لاروش ايه جي Erythropoietin derivatives
US6461802B1 (en) 1999-08-02 2002-10-08 Agfa-Gevaert Adhesive layer for polyester film
EP1235842A4 (en) 1999-10-15 2003-04-23 Univ Massachusetts Rna interference pathway genes as tools for targeted genetic interference
DE60026073T2 (de) 1999-12-22 2006-09-28 Nektar Therapeutics Al, Corp., Huntsville Sterisch gehinderte derivate von wasserlöslichen polymeren
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
US20030212021A1 (en) 2001-01-25 2003-11-13 Frost Gregory I. Myeloid colony stimulating factor and uses thereof
ES2259024T3 (es) 2000-01-25 2006-09-16 Sidney Kimmel Cancer Center Factor estimulador de colona mieloide y usos del mismo.
US6602498B2 (en) 2000-02-22 2003-08-05 Shearwater Corporation N-maleimidyl polymer derivatives
DE10013735A1 (de) * 2000-03-23 2001-10-11 Bakelite Ag Härter für Epoxidverbindungen, Verfahren zu ihrer Herstellung und Verwendung
TWI246524B (en) 2001-01-19 2006-01-01 Shearwater Corp Multi-arm block copolymers as drug delivery vehicles
US6745776B2 (en) 2001-04-10 2004-06-08 David B. Soll Methods for reducing postoperative intraocular pressure
FR2827377B1 (fr) * 2001-07-13 2003-12-05 Poudres & Explosifs Ste Nale Dispositif d'allumage pour microcharges pyrotechniques
US20040224012A1 (en) 2001-10-05 2004-11-11 Pichit Suvanprakorn Topical application and methods for administration of active agents using liposome macro-beads
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
MXPA04004336A (es) 2001-11-07 2005-05-16 Nektar Therapeutics Al Corp Polimeros ramificados y sus conjugados.
AU2002351197A1 (en) * 2001-11-28 2003-06-10 Neose Technologies, Inc. Glycopeptide remodeling using amidases
US7064110B2 (en) 2002-05-13 2006-06-20 Enanta Pharmaceuticals, Inc. 6-11 bicycle ketolide derivatives
US7049483B1 (en) 2002-07-15 2006-05-23 Bruce Eric Hudkins Transgenic bioluminescent plants
US6682904B1 (en) 2002-08-15 2004-01-27 Deliatroph Pharmaceuticals, Inc. Specific inhibitors of hyaluronidase 2, and methods of identifying and using same
KR20040040782A (ko) 2002-11-08 2004-05-13 선바이오(주) 신규한 헥사-암 폴리에틸렌글리콜과 유도체 및 그의합성방법
EP2218779A1 (en) 2002-12-16 2010-08-18 Halozyme, Inc. Human chondroitinase glycoprotein (chasegp), process for preparing the same, and pharmaceutical compositions comprising thereof
US6969514B2 (en) * 2003-02-05 2005-11-29 Soll David B Method for treating elevated intraocular pressure, including glaucoma
US7767429B2 (en) * 2003-03-05 2010-08-03 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US20090123367A1 (en) 2003-03-05 2009-05-14 Delfmems Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
CA2519680A1 (en) 2003-03-28 2004-11-18 The Scripps Research Institute Adenovirus particles with enhanced infectivity of dendritic cells and particles with decreased infectivity of hepatocytes
US7610156B2 (en) 2003-03-31 2009-10-27 Xencor, Inc. Methods for rational pegylation of proteins
EP1616004A1 (en) 2003-04-15 2006-01-18 Ista Pharmaceuticals, Inc Process for isolating and purifing ovine hyaluronidase
ES2336917T3 (es) 2003-04-30 2010-04-19 Trine Pharmaceuticals, Inc. Antibioticos betalactamicos de la clase de los carbacefem.
KR100512483B1 (ko) 2003-05-07 2005-09-05 선바이오(주) 신규한 폴리에틸렌글리콜-말레이미드 유도체의 합성방법
US7429375B2 (en) 2003-05-16 2008-09-30 Acorda Therapeutics, Inc. Proteoglycan degrading mutants for the treatment of CNS
JP4934796B2 (ja) 2003-08-14 2012-05-16 トロンボジェニクス・ナムローゼ・フエンノートシャップ 可変抗体
WO2005030927A2 (en) 2003-09-23 2005-04-07 Uab Research Foundation Methods and compositions for in vivo inflammation monitoring
WO2005118799A1 (en) 2004-04-15 2005-12-15 Ista Pharmaceuticals, Inc. Ovine hyaluronidase
KR20070057767A (ko) 2004-06-15 2007-06-07 앤드류 셴 천 인지질 조성물 및 이의 제조 및 사용 방법
US7572613B2 (en) 2004-06-25 2009-08-11 Klein Jeffrey A Drug delivery system for accelerated subcutaneous absorption
JP3912395B2 (ja) 2004-07-12 2007-05-09 セイコーエプソン株式会社 半導体集積回路、検査装置および半導体集積回路の検査方法
US20060292682A1 (en) 2004-07-22 2006-12-28 Hawkins Lynda K Addition of transgenes into adenoviral vectors
US20060181032A1 (en) * 2005-02-11 2006-08-17 Riggs Robert A Hybrid gasket
US7976833B2 (en) 2005-10-14 2011-07-12 Aspen Biomedical Research, Llc Ophthalmic surgical irrigating solutions containing hyaluronidase and method for preventing post-operative intraocular pressure increases
WO2007059473A2 (en) 2005-11-12 2007-05-24 Introgen Therapeutics, Inc. Methods for the production and purification of adenoviral vectors
WO2007098479A2 (en) 2006-02-21 2007-08-30 University Of Medicine And Dentistry Of New Jersey Localized insulin delivery for bone healing
US8170830B2 (en) 2006-08-22 2012-05-01 Jacobs James P Method and system for providing tolerance to interference and obstructions of line of sight
JPWO2009001670A1 (ja) 2007-06-05 2010-08-26 帝人株式会社 ポリカーボネート樹脂組成物
US8288142B2 (en) 2007-06-19 2012-10-16 Uvarkina Tamara P Hyaluronidase and method of use thereof
JP4931230B2 (ja) 2007-06-22 2012-05-16 新菱冷熱工業株式会社 クリーンルームの空調方法及び空調装置
US8956412B2 (en) 2007-06-22 2015-02-17 Axiomed, LLC Artificial disc
US20080314349A1 (en) 2007-06-25 2008-12-25 Robert Bosch Gmbh Green start engine control systems and methods
WO2009001455A1 (ja) 2007-06-27 2008-12-31 Hitachi, Ltd. プラズマディスプレイ装置
CA2717383C (en) 2008-03-06 2017-01-03 Halozyme, Inc. Large-scale production of soluble hyaluronidase
TWI395593B (zh) 2008-03-06 2013-05-11 Halozyme Inc 可活化的基質降解酵素之活體內暫時性控制
TWI532498B (zh) 2008-03-17 2016-05-11 巴克斯特保健公司 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
WO2009128918A1 (en) 2008-04-14 2009-10-22 Halozyme, Inc. Combination therapy using a soluble hyaluronidase and a bisphosphonate
EP2662090A1 (en) 2008-04-14 2013-11-13 Halozyme, Inc. Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
TWI394580B (zh) 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
US8315366B2 (en) * 2008-07-22 2012-11-20 Shoretel, Inc. Speaker identification and representation for a phone
EA036569B1 (ru) 2008-12-09 2020-11-24 Галозим, Инк. Способ получения полипептида гиалуронидазы ph20
US20110229451A2 (en) 2009-03-06 2011-09-22 Halozyme, Inc. Temperature sensitive mutants of matrix metalloproteases and uses thereof
ES2385251B1 (es) 2009-05-06 2013-05-06 Fundació Privada Institut D'investigació Biomèdica De Bellvitge Adenovirus oncolíticos para el tratamiento del cáncer.
US20100305500A1 (en) 2009-05-29 2010-12-02 Pacira Pharmaceuticals, Inc. Hyaluronidase as an adjuvant for increasing the injection volume and dispersion of large diameter synthetic membrane vesicles containing a therapeutic agent
CN102655853B (zh) 2009-09-17 2015-07-29 巴克斯特卫生保健有限公司 透明质酸酶和免疫球蛋白的稳定的复合制剂及其使用方法
MX348420B (es) 2010-07-20 2017-06-12 Halozyme Inc Efectos secundarios adversos asociados con la administracion de agentes anti-hialuronano y metodos para mejorar o prevenir los efectos secundarios.
MX349622B (es) 2010-09-08 2017-08-07 Halozyme Inc Metodos para evaluar e identificar o evolucionar proteinas terapeuticas condicionalmente activas.
ES2634669T3 (es) * 2011-02-08 2017-09-28 Halozyme, Inc. Composición y formulación lipídica de una enzima de degradación de hialuronano y uso de la misma para el tratamiento de la hiperplasia benigna de próstata
MX341448B (es) * 2011-06-17 2016-08-19 Halozyme Inc Metodos de infusion de insulina subcutanea continua con una enzima que degrada a hialuronano.
US9993529B2 (en) * 2011-06-17 2018-06-12 Halozyme, Inc. Stable formulations of a hyaluronan-degrading enzyme
EP2768521B1 (en) 2011-10-18 2016-07-13 CSL Behring GmbH Combined use of a sulfated glycosaminoglycan and a hyaluronidase for improving the bioavailability of factor viii
AU2012328880B2 (en) * 2011-10-24 2017-02-23 Halozyme, Inc. Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof
WO2013102144A2 (en) 2011-12-30 2013-07-04 Halozyme, Inc. Ph20 polypeptede variants, formulations and uses thereof
NZ700073A (en) 2012-04-04 2016-08-26 Halozyme Inc Combination therapy with an anti - hyaluronan agent and a tumor - targeted taxane
CN105727267B (zh) 2016-02-05 2020-05-26 苏州康聚生物科技有限公司 一种重组人透明质酸酶冻干制剂及其制备方法和应用
WO2020022791A1 (ko) 2018-07-25 2020-01-30 (주)알테오젠 신규 히알루론산 가수분해 효소 변이체 및 이를 포함하는 약제학적 조성물

Also Published As

Publication number Publication date
AU2004218354A1 (en) 2004-09-16
US20090214505A1 (en) 2009-08-27
PT2177620E (pt) 2015-02-16
EP2405015A2 (en) 2012-01-11
ES2335005T5 (es) 2013-04-17
US8431124B2 (en) 2013-04-30
AU2009245838A1 (en) 2010-01-07
US20120148555A1 (en) 2012-06-14
EP2405015B1 (en) 2016-01-06
ATE448323T1 (de) 2009-11-15
CN1942588B (zh) 2013-06-12
DK1603541T3 (da) 2010-03-29
KR20120094493A (ko) 2012-08-24
SG2012041067A (en) 2014-08-28
US11723959B2 (en) 2023-08-15
PT2163643E (pt) 2015-05-18
EA200501384A1 (ru) 2006-06-30
US10898551B2 (en) 2021-01-26
CY2015033I2 (el) 2016-06-22
HUE027661T2 (en) 2016-10-28
US20190224286A1 (en) 2019-07-25
EP2163643B1 (en) 2015-01-21
WO2004078140A3 (en) 2005-11-17
JP2013031446A (ja) 2013-02-14
US20210023184A1 (en) 2021-01-28
US9562223B2 (en) 2017-02-07
US20120251620A1 (en) 2012-10-04
AU2009245838B2 (en) 2013-05-09
US8450470B2 (en) 2013-05-28
KR20110114692A (ko) 2011-10-19
SI2177620T1 (sl) 2015-02-27
US8772246B2 (en) 2014-07-08
EP2163643A1 (en) 2010-03-17
CN1942588A (zh) 2007-04-04
EP2311973A1 (en) 2011-04-20
DK1603541T4 (da) 2013-04-15
US20230321203A1 (en) 2023-10-12
US20170246264A1 (en) 2017-08-31
PT1603541E (pt) 2010-02-19
US20090181032A1 (en) 2009-07-16
PL2177620T3 (pl) 2015-05-29
ES2564103T3 (es) 2016-03-17
FR16C0030I1 (fr) 2016-08-26
PL1603541T3 (pl) 2010-04-30
DK2405015T3 (en) 2016-03-21
NZ542873A (en) 2008-07-31
US20090181013A1 (en) 2009-07-16
KR101363658B1 (ko) 2014-02-14
US9677062B2 (en) 2017-06-13
CY1109750T1 (el) 2014-09-10
IL227867A (en) 2015-09-24
JP5538770B2 (ja) 2014-07-02
US20130058893A1 (en) 2013-03-07
PL2405015T3 (pl) 2016-09-30
CA2517145C (en) 2017-08-01
CN102943067B (zh) 2016-06-22
SI2163643T1 (sl) 2015-03-31
PL2163643T3 (pl) 2015-06-30
US20110152359A1 (en) 2011-06-23
EP1603541B1 (en) 2009-11-11
SI1603541T2 (sl) 2013-04-30
US10286044B2 (en) 2019-05-14
IL170300A (en) 2016-06-30
HK1138885A1 (en) 2010-09-03
CY1116110T1 (el) 2017-02-08
EA009383B1 (ru) 2007-12-28
EP2177620B1 (en) 2014-11-19
IL227867A0 (en) 2013-09-30
EP2330213A1 (en) 2011-06-08
BRPI0408116B1 (pt) 2022-09-20
EP3009517A1 (en) 2016-04-20
JP4464395B2 (ja) 2010-05-19
HK1138883A1 (en) 2010-09-03
DK2163643T3 (en) 2015-03-23
LU93138I2 (fr) 2016-09-05
CY2016024I2 (el) 2017-06-28
PL1603541T5 (pl) 2013-06-28
KR20050118273A (ko) 2005-12-16
EP1603541A2 (en) 2005-12-14
AU2004218354B2 (en) 2009-10-01
EP1603541B2 (en) 2013-01-23
CY1117358T1 (el) 2017-04-26
JP5756785B2 (ja) 2015-07-29
US7767429B2 (en) 2010-08-03
HK1165834A1 (en) 2012-10-12
US8431380B2 (en) 2013-04-30
US8765685B2 (en) 2014-07-01
EP2177620A1 (en) 2010-04-21
EP2405015A3 (en) 2012-03-07
KR20130135986A (ko) 2013-12-11
DK2177620T3 (en) 2015-01-26
CA2517145A1 (en) 2004-09-16
JP2006524507A (ja) 2006-11-02
KR101233457B1 (ko) 2013-02-15
CY1116370T1 (el) 2016-06-22
US20140199282A1 (en) 2014-07-17
ES2335005T3 (es) 2010-03-18
ES2532399T3 (es) 2015-03-26
SI1603541T1 (sl) 2010-03-31
DE602004024041D1 (de) 2009-12-24
US20040268425A1 (en) 2004-12-30
ZA200507978B (en) 2007-03-28
LU92780I9 (pt) 2024-05-13
HUS1600031I1 (hu) 2016-08-29
MXPA05009429A (es) 2005-12-12
SG177008A1 (en) 2012-01-30
HK1086746A1 (en) 2006-09-29
US9677061B2 (en) 2017-06-13
ES2526536T3 (es) 2015-01-13
SI2405015T1 (sl) 2016-04-29
LU92780I2 (fr) 2015-09-21
CY2015033I1 (el) 2016-06-22
WO2004078140A2 (en) 2004-09-16
CY2016024I1 (el) 2017-06-28
EP1603541A4 (en) 2006-11-22
CN102943067A (zh) 2013-02-27
JP2010029190A (ja) 2010-02-12
US20090253175A1 (en) 2009-10-08
US8202517B2 (en) 2012-06-19

Similar Documents

Publication Publication Date Title
BRPI0608314A2 (pt) composição farmacêutica compreendendo hialuronidase (shasegp), composição farmacêutica e uso da glicoproteìna hialuronidase, hialuronidase peguilada, composição farmacêutica e uso da hialuronidase peguilada, método de preparação de uma hialuronidase peguilada e combinações das referidas hialuronidases
WO2004078140A3 (en) SOLUBLE HYALURONIDASE GLYCOPROTEIN (sHASEGP), PROCESS FOR PREPARING THE SAME, USES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEREOF
ES2296914T3 (es) Farmacos de serpina para el tratamiento de la infeccion por vih y metodo de uso de los mismos.
EP4461811A3 (en) Pharmaceutical composition, comprising human hyaluronidase ph20 variant and drug, for subcutaneous injection
BR0108173A (pt) Composições farmacêuticas de toxina de botulina
JP2008522617A5 (pt)
TW200605909A (en) Pharmaceutical preparation of recombinant factor VIII lyophilized without albumin as a stabilizer
WO2022256499A3 (en) Bcma targeting trispecific proteins and methods of use
AU7617796A (en) Variants of human recombinant interferon-gamma (rhu-ifn-gamma) having increased heat-stability
IT1299583B1 (it) Uso di proteine hmg-i per la preparazione di medicamenti ad attivita' citotossica
DK1635776T5 (da) Lipidoverf ringsproteinsystemer samt deres kosmetiske dermatologiske anvendelse
WO2002081507A3 (en) Interferon gamma polypeptide variants
WO2025075975A9 (en) Peptides from regenerative species and methods for use thereof
DK0456153T3 (da) Galeniske vandige formuleringer af erythopoietin og deres anvendelse
AR123698A1 (es) Formulaciones para administración supracoroidal tales como formulaciones con formación de agregados
WO2025054236A3 (en) Sars-cov-2 vaccine compositions and related methods

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B12C Appeal against dismissal [chapter 12.3 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 9A E 10A ANUIDADES.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/03/2004, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B21H Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 21.6 NA RPI NO 2822 DE 04/02/2025 POR TER SIDO INDEVIDA.